Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Depreciation & Amortization (CF) (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed Depreciation & Amortization (CF) for 5 consecutive years, with $72000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 278.95% to $72000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $600000.0, a 47.42% increase, with the full-year FY2024 number at $500000.0, up 66.67% from a year prior.
  • Depreciation & Amortization (CF) was $72000.0 for Q3 2025 at Lyra Therapeutics, down from $200000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $400000.0 in Q3 2021 to a low of -$68000.0 in Q3 2023.
  • A 5-year average of $176736.8 and a median of $200000.0 in 2024 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): plummeted 122.67% in 2023, then surged 886.96% in 2024.
  • Lyra Therapeutics' Depreciation & Amortization (CF) stood at $300000.0 in 2021, then dropped by 26.0% to $222000.0 in 2022, then crashed by 51.8% to $107000.0 in 2023, then soared by 86.92% to $200000.0 in 2024, then crashed by 64.0% to $72000.0 in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Depreciation & Amortization (CF) are $72000.0 (Q3 2025), $200000.0 (Q2 2025), and $128000.0 (Q1 2025).